Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Animal models of systemic sclerosis: prospects and limitations.

Literature DB >> 20617524

Animal models of systemic sclerosis: prospects and limitations.

Christian Beyer¹, Georg Schett, Oliver Distler, Jörg H W Distler.

Abstract

Entities: Disease

Mesh：

Year: 2010 PMID： 20617524 DOI： 10.1002/art.27647

Source DB: PubMed Journal: Arthritis Rheum ISSN： 0004-3591

Keyword Cloud
Cited

× No keyword cloud information.

49 in total

1. Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors: Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal: J Cell Commun Signal Date: 2012-05-31 Impact factor: 5.782

Review 2. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

Authors: Oliver Distler; Antonio Cozzio
Journal: Semin Immunopathol Date: 2015-11-17 Impact factor: 9.623

3. Mouse Models of Skin Fibrosis.

Authors: Aleix Rius Rigau; Markus Luber; Jörg H W Distler
Journal: Methods Mol Biol Date: 2021

Review 4. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.

Authors: Naoki Iwamoto; Jörg H W Distler; Oliver Distler
Journal: Curr Rheumatol Rep Date: 2011-02 Impact factor: 4.592

Review 5. Myeloid Populations in Systemic Autoimmune Diseases.

Authors: María Morell; Nieves Varela; Concepción Marañón
Journal: Clin Rev Allergy Immunol Date: 2017-10 Impact factor: 8.667

Review 6. Targeted therapies for systemic sclerosis.

Authors: Christopher P Denton; Voon H Ong
Journal: Nat Rev Rheumatol Date: 2013-04-09 Impact factor: 20.543

7. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB₂ receptor-dependent pathways.

Authors: Carmen Del Rio; Irene Cantarero; Belén Palomares; María Gómez-Cañas; Javier Fernández-Ruiz; Carolina Pavicic; Adela García-Martín; Maria Luz Bellido; Rafaela Ortega-Castro; Carlos Pérez-Sánchez; Chary López-Pedrera; Giovanni Appendino; Marco A Calzado; Eduardo Muñoz
Journal: Br J Pharmacol Date: 2018-08-23 Impact factor: 8.739

Animal models of systemic sclerosis: prospects and limitations.

1. Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Review 2. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

3. Mouse Models of Skin Fibrosis.

Review 4. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.

Review 5. Myeloid Populations in Systemic Autoimmune Diseases.

Review 6. Targeted therapies for systemic sclerosis.

7. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB₂ receptor-dependent pathways.

Review 8. Diagnosis and Management of Systemic Sclerosis: A Practical Approach.

Review 9. Surgical approaches to create murine models of human wound healing.

Review 10. The immune pathogenesis of scleroderma: context is everything.

Animal models of systemic sclerosis: prospects and limitations.

1. Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Review 2. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.

3. Mouse Models of Skin Fibrosis.

Review 4. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.

Review 5. Myeloid Populations in Systemic Autoimmune Diseases.

Review 6. Targeted therapies for systemic sclerosis.

7. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB2 receptor-dependent pathways.

Review 8. Diagnosis and Management of Systemic Sclerosis: A Practical Approach.

Review 9. Surgical approaches to create murine models of human wound healing.

Review 10. The immune pathogenesis of scleroderma: context is everything.

7. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPARγ- and CB₂ receptor-dependent pathways.